Bluewater Bio has attracted interest from several parties in acquiring the business from its current shareholder Salica. Rothschild & Co’s UK mid-market team and BDA have been called in to act as advisors on a potential sale.
Bluewater Bio says it has achieved an impressive Annual Compound Growth Rate of 38% over 3 years, with its FilterClear Technology reaching 83%, in the same period. This year, the company has secured 86% of its £40m forecast in the first 3 months. As a major exporter to markets outside the US, the business says it has strong insulation against rising tariffs, positioning it as a resilient business in the current environment.
The company aslo says its two major technologies HYBACS and FilterClear are well established and achieve market leading performance in Water and Wastewater treatment. An example is Phosphorous removal where the UK is undergoing a long term, large scale improvement programme lasting to at least 2035 and overseas where rapidly increasing desalination pretreatment is being focussed on FilterClear technology.
Richard Haddon, Bluewater Bio’s CEO & Executive Chair, said:
“We have grown and developed beyond expectations and have incredible traction both in the UK and overseas which has attracted investor interest. We have plans to further accelerate growth and this could be the time to bring in fresh investment to underpin the next stage in our strategy. With the global realisation for the importance of environmentally friendly water treatment, our technology is highly sought after and for us to match demand and continue to match the needs of our clients, this is an optimum moment to consider further investment. Our technologies reduce capital and operating costs, operating plant size, environmental damage and construction times. We are excited about the long-term strategic opportunity to help water companies become more efficient in how they invest and operate.”
According to the company, its FilterClear and HYBACS systems are in high demand both in the UK, where water companies are under pressure to meet environmental and service commitments, and across the Middle East, where the need for scalable water and wastewater treatment for both drinking water and irrigation is significantly growing year-on-year. The company has recently entered an agreement with a significant Middle Eastern water operator, which will open new opportunities and markets around the world.
Bluewater Bio was founded in 2009, with the current management team reaching their 10th year in post. The company is based in Marylebone in London, with satellite offices in the Middle East.